SAN FRANCISCO--(BUSINESS WIRE)-- <\/p>\n
CollabRx, Inc. (CLRX) today announced a multi-year partnership agreement with Life Technologies Corporation for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologiesglobal cancer diagnostics development and its laboratory developed test services business. The agreement represents a major step forward by CollabRx in providing laboratories and next-generation sequencing (NGS) companies with meaningful insights into cancer. <\/p>\n
Molecular analysis, including genetic sequencing, is increasingly becoming an important part of the clinical management of cancer patients, said James Karis, Co-CEO of CollabRx. However, the sheer volume and complexity of genetic data that is being produced, particularly in the course of therapy development, is outpacing the ability of practicing physicians to stay current, and more importantly understand how to apply this genetic data in treating their patients. <\/p>\n
CollabRx, Inc., a data analytics company focused on genomics, bridges this knowledge gap using cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the worlds knowledge on molecular medicine with specific insights from the nations top clinical experts. <\/p>\n
Life Technologies will use CollabRx proprietary content and technology to pair the results of broad molecular profiling panels developed by Life Technologies with associated clinically relevant and dynamically updated knowledge on clinical trials, drugs, biologics and other information relevant for cancer treatment planning. This knowledge is supported by CollabRxs large and growing network of over 50 leading clinical practitioners in the United States. While CollabRx and its advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the context engine for informing healthcare decision-making. <\/p>\n
Its critical to contextualize the results of complex cancer panels to make them useful for interpreting and treating physicians, saidRonnie Andrews, president of Medical Sciences atLife Technologies. CollabRx has pioneered the development of a scalable platform and process to provide actionable, accessible, and credible knowledge at the point of care to aid physicians in developing a cancer treatment plan based on tumor molecular profiles. We are excited to include this key capability with our molecular diagnostic tests. <\/p>\n
As the genomics revolution continues to unfold, successful cancer diagnostic companies will need cutting-edge technologies as well as deep, personalized analytics, said Thomas Mika, Co-CEO of CollabRx. We are thrilled to be a part of Life Technologies strategy to establish a leadership position in the clinical diagnostics market by providing ordering physicians with clinically relevant interpretation of test results, personalized for each patient, as a seamless part of the reporting process via Web-based and mobile technologies. <\/p>\n
About CollabRx <\/p>\n
CollabRx, Inc. (CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the worlds knowledge on genomics-based medicine with specific insights from the nations top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http:\/\/www.collabrx.com<\/a>. <\/p>\n CollabRx Safe Harbor Statement <\/p>\n<\/p>\n See the original post here: <\/p>\n CollabRx Partners with Life Technologies in Molecular Diagnostics<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" SAN FRANCISCO--(BUSINESS WIRE)-- CollabRx, Inc. (CLRX) today announced a multi-year partnership agreement with Life Technologies Corporation for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologiesglobal cancer diagnostics development and its laboratory developed test services business. The agreement represents a major step forward by CollabRx in providing laboratories and next-generation sequencing (NGS) companies with meaningful insights into cancer Continue reading